F.Sh. Akhmetzyanov1,2, A.V. Karamanyan1,3, R.F. Akhmetzyanova2, G.N. Khusainova2, Yu.S. Batinova1, Z.Kh. Garaeva1, Kh.M. Nguen1, A.N. Fayrushina2, O.V. Karamanyan1, E.L. Rashitova1

1Kazan State Medical University, Kazan

2Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic named after prof. M.Z. Sigal, Kazan

3Medical and sanitary unit of the Kazan (Volga Region) Federal University, clinic, Kazan

Karamanyan Angelina V. ― postgraduate student, assistant of the Department of Oncology, Radiation Diagnostics and Radiation Therapy of the Kazan State Medical University

49 Butlerov Str., Kazan, 420012, Russian Federation, tel. +7-917-299-51-88, e-mail, ORCID ID: 0000-0001-7168-337X


Introduction. According to the literature, the paper presents the epidemiology and clinical and histological characteristics of non-Hodgkin lymphoma (NHL) and the analysis of the dependence of the results of NHL treatment on the time of initiation of therapy. The general characteristics of immunohistochemical and molecular-genetic characteristics of diffuse large B-cell lymphoma are presented, which may have prognostic value in treatment.

Aim ― to assess the relationship between the results of treatment and the timing of diagnosis and the start of treatment.

Material and methods. Retrospective analysis of the survival rate of 93 patients of different ages from 30 to 80 years old with various types and subtypes of non-Hodgkin’s lymphomas treated in the Department of the State Healthcare Institution of the Regional Clinical Hospital of the Ministry of Health of the Republic of Tatarstan, depending on the time of diagnosis before the start of treatment. All patients underwent a PET CT scan prior to treatment. The patients were divided into two forms: follicular ― 55 people, aggressive ― 38 people. Statistical processing was performed using the Statistical Package for the Social Science’s software program (version 20.0), 95% CI.

Results and discussions. Our study suggests that the time from diagnosis to treatment is an important risk factor, independent of other clinical and sociodemographic characteristics. Patients with aggressive lymphoma who started chemotherapy within the first month of diagnosis had higher one-year survival rates compared to patients treated at 2 months and 3 months after diagnosis, 74,5%, 61,9%, and 41,3%, respectively. Follicular lymphoma patients admitted for treatment for one, two, three, and more than 3 months had corresponding scores of 89,0; 71,4; 70,3; 63,6%.

Conclusions. Our study shows that the time to start of treatment can be a good indicator in accounting for and determining the initiation of treatment depending on the aggressiveness of lymphomas, which remains unaccounted for in the MPI despite the fact that the index includes general condition, clinical stage of the disease, complete and biochemical blood counts.

Key words: malignant lymphomas, indolent lymphomas, aggressive lymphomas, lymphoma treatment.